Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial

Crowther, Mark; Julian, Jim A.; McCarty, Donna; Douketis, James D.; Kovacs, Michael J.; Biagoni, Lee; Schnurr, Terri; McGinnis, Joanne; Gent, Michael; Hirsh, Jack; Ginsberg, JS

doi:10.1016/s0140-6736(00)03125-1

Cited by 164 publications

(141 citation statements)

References 8 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…W czterech RCT porównano witaminę K1 z placebo u pacjentów z INR w zakresie 4,5-10, u których nie stwierdzono aktywnego krwawienia [260][261][262][263]. U pacjentów otrzymujących witaminę K1 obserwowano gwałtowniejszy spadek wartości INR, nie stwierdzono jednak korzyści pod względem klinicznie istotnych zdarzeń, obejmujących poważne krwawienia lub epizody zakrzepowo-zatorowe.…”

Section: Krwawienie W Trakcie Stosowania Antagonistów Witaminy Kunclassified

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Roffi¹,

Patrono²,

Collet³

et al. 2015

Kardiol Pol

210

165

View full text Add to dashboard Cite

Section: Krwawienie W Trakcie Stosowania Antagonistów Witaminy Kunclassified

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Roffi¹,

Patrono²,

Collet³

et al. 2015

Kardiol Pol

210

165

View full text Add to dashboard Cite

“…[21][22][23][24][25][26][27] Furthermore, oral vitamin K simplifies the out-of-hospital management of asymptomatic VKA-associated coagulopathy.…”

Section: Management Of the Non-bleeding Patient With High Inrmentioning

confidence: 99%

“…[23][24][25]28,31 However, a recent large randomized controlled trail including more than 700 patients with INR values between 4.5 and 10.0 failed to show a statistically significant reduction in major bleeding events in the group of patients randomized to 1.25 mg of oral vitamin K compared with the group of patients randomized to placebo. 32 No studies have directly compared the efficacy of differing doses of oral vitamin K. A recent cumulative analysis of the available literature does suggest, however, that the optimal dose of oral vitamin K is 1 to 1.25 mg for patients with INR values between 4.5 and 10.0, and 2.5 mg for patients with INR values of more than 10.0.…”

Section: Management Of the Non-bleeding Patient With High Inrmentioning

confidence: 99%

Management of Excessive Anticoagulant Effect Due to Vitamin K Antagonists

Dentali

Crowther²

2008

Hematology

View full text Add to dashboard Cite

Coagulation factor replacement is required given the need to urgently correct the INR; however, vitamin K should not be forgotten since it is required to antagonize the effect of warfarin, preventing "rebound" anticoagulation after transfused coagulation factors are consumed. This paper will review the evidence supporting various treatment modalities and will provide suggestions for treatment. Future advances in this area will likely focus on evaluations of the relative merits of FFP and PCCs.

show abstract

“…Comparing these data with those of Pendry et al (2001) is complicated by the different dosing regimens. However, two studies in which Crowther et al (1998Crowther et al ( , 2000 have reported on the effect of administration of 1 mg of the parenteral preparation of vitamin K by mouth suggest that there are marked differences in the ef®cacy of reversal of anticoagulation between orally administered preparations of vitamin K.…”

mentioning

confidence: 99%

“…Pendry et al (2001) administered this in the form of Orakay, a gelatine capsule, while Crowther et al (2000) administered 1 mg of the intravenous preparation by mouth. Twenty-four hours after the administration of Orakay, correction to an INR of < 4á5 was seen in only 40% (12 ¤ 30) of patients, while 73% (33 ¤ 45) of recipients of the intravenous preparation and 20% (9 ¤ 44) of placebo recipients had achieved an INR of < 3á2.…”

mentioning

confidence: 99%